WednesdayAug 10, 2022 2:34 pm

Leading Neuroscientist Explains How Psychedelics Alters the Brain

We have seen interest in psychedelics grow significantly these last few years as more studies into the therapeutic potential of the substance has been conducted. Psychedelics are substances that alter the function of an individual’s brain when ingested. This may result in changes in their mood, perception and cognitive processes. Common psychedelics include mescaline, psilocybin, ayahuasca and peyote. Despite the fact that humans have known about and used these hallucinogens for millennia, there is still a lot we are uncertain about when it comes to these substances and how they can benefit us. Below, we look at what we’ve learned…

Continue Reading

TuesdayAug 09, 2022 1:59 pm

Compass Pathways to Begin New Phase 2 Psychedelic Trial for Anorexia

Compass Pathways PLC (NASDAQ: CMPS) is a mental health care company that is focused on improving patient access to evidence-based innovation in mental health. The company’s stock, which trades as CMPS on the NASDAQ has been performing well, with many attributing this positive performance to the appointment of a new CEO. The company recently announced that it would be launching a new phase 2 trial on the use of its COMP360 formulation in treating anorexia. The company will conduct the trial at various prestigious research institutions in the United States and the United Kingdom, including Columbia University’s Irving Medical Center,…

Continue Reading

MondayAug 08, 2022 2:31 pm

Toronto Firm Receives First Federal Government Funding to Study Psilocybin

After decades of prohibition, Canada is finally opening the door to psychedelic research. Canada banned psychedelics nearly 50 years ago, outlawing the production and use of psychedelic drugs such as psilocybin, the main psychoactive agent in magic mushrooms, and making it nearly impossible to research these drugs. However, the winds have been shifting in favor of psychedelics in recent years as more people have begun using them to address mental health conditions including (PTSD) and  major depressive disorder. A Toronto-based company has now received Canada’s first-ever federal government funding to run a study on the impact of psilocybin on depression.…

Continue Reading

FridayAug 05, 2022 10:42 am

Legislators in San Francisco File Initiative to Locally Decriminalize Psychedelics

Last week, legislators in San Francisco filed a measure to locally decriminalize psychedelics such as ayahuasca and psilocybin. The resolution, which also calls for broader statewide reform, was sponsored by Supervisors Hillary Ronen and Dean Preston. The measure’s enactment by the Board of Supervisors would make the city of San Francisco the largest in the country by population to deprioritize the enforcement of laws that prohibit entheogenic substances. The “whereas” section of the proposal talks about the traditional role that psychedelics play as catalysts for profound experiences of spiritual and personal growth, as well as the therapeutic potential of these…

Continue Reading

ThursdayAug 04, 2022 12:55 pm

Three Clinical Trials On Psychedelic Microdosing Worth Following

As more research on the therapeutic benefits of psychedelics is conducted, concerns about whether microdosing works continue to grow, as many believe that the supposed benefits may be solely because of the placebo effect. It doesn’t help that data from placebo-controlled trials is inconclusive, which only means that the best way to find out whether microdosing is actually effective is to carry out properly controlled microdosing clinical trials. The following are a few of the ongoing microdosing clinical trials. Filament Health’s psilocybin clinical trial Earlier in the year, Filament Health announced that it was launching a phase II psilocybin microdosing…

Continue Reading

WednesdayAug 03, 2022 12:33 pm

New Poll Finds Most Americans Support Research on Psychedelics for Military Members

A recently conducted poll has found that most Americans support the study of substances such as MDMA and psilocybin as alternative options for mental health treatment for military service members. Bipartisan legislators championing for policy issues such as the promotion of research on psychedelics and the legalization of cannabis appear to have plenty of support from Americans, despite Congress receiving criticism for not aligning with its constituents on such matters. The YouGov poll, which was conducted between July 22—25, 2022, found that nearly 55% of Americans were in favor of permitting studies into the therapeutic potential of a range of…

Continue Reading

WednesdayAug 03, 2022 12:00 pm

Silo Pharma Inc.’s (SILO) Ketamine Study Produces Positive Endpoint Results, Suggests Topical Formulation Reduces Neuropathic Nerve Pain

Silo recently completed ketamine study showing neuropathic nerve pain reduction when administered with patented, partnered delivery system Results of study demonstrated Silo’s topical ketamine formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, mechanical hyperalgesia reduced on day seven at the pre-dose time point Ketamine typically used to induce and maintain anesthesia, drug use expanding to include depression and chronic pain treatment at subanesthetic doses Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, recently completed a study of its ketamine formulation, showing nerve pain reduction when administered using a patented delivery system developed in partnership…

Continue Reading

TuesdayAug 02, 2022 1:22 pm

Fruitfly Research Model Finds That Single Psilocybin Dose Has Long-Lasting Antidepressant-Like Effects

A new study has looked into the effects of psilocybin at a genetic and cellular level using fruit flies, because their neurotransmitter systems are similar to those of mammals. This has led to the discovery that one dose of the active compound produces a long-lasting, antidepressant-like effect in fruit flies. Psilocybin is the active compound found in magic mushrooms that produces changes in time perception, sensory perception, mood and sense of self. This can alter the way an individual experiences the world around them. Preliminary studies have shown that administering psilocybin in conjunction with psychotherapy may result in lasting improvements…

Continue Reading

MondayAug 01, 2022 11:37 am

The DEA Rescinds Proposal to Ban Five Psychedelics

The Drug Enforcement Administration (DEA) recently withdrew a proposal to ban certain psychedelics, stating that it had instead decided to request for an updated review of the psychedelic compounds from the Department of Health and Human Services (DHHS). The DEA had first proposed that the DiPT, 5-MeO-DET, 5-MeO-MiPT, 5-MeO-AMT and 4-OH-DiPTtryptamines be scheduled earlier in the year. Tryptamines are psychedelic and hallucinogenic drugs that cause users to experience hallucinations as well as euphoria. However, after the announcement, the agency faced criticism on the matter and received hundreds of messages opposing the change and asking for a hearing. Through its own…

Continue Reading

FridayJul 29, 2022 12:03 pm

Research Finds Psychedelics May Open Door to Self-Actualization

According to Maslow’s Hierarchy of Needs, self-actualization is the realization of an individual's full potential and the complete development of their ability to enjoy and appreciate life. The highest level of psychological development, self-actualization, is only achievable once an individual have met their physiological, safety, belongingness, love and esteem needs. However, life tends to throw plenty of trials and tribulations that act as barriers to self-actualization, with Maslow estimating that just 1% of adults have self-actualized. Recent research into a federally controlled class of drugs has revealed an interesting fact: psychedelics have the ability to help people self-actualize. Individuals who…

Continue Reading

PsychedelicNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 415.949.5050